Treatment Effectiveness and Side Effects: A Model of Physician Learning

In this paper we study how treatment effectiveness and side effects impact the prescription decision of a risk-averse physician, and how detailing and patient feedback help reduce the physician's uncertainty in these two attributes in the erectile dysfunction category. To separately identify the impacts of effectiveness and side effects, we augment the observed prescription choices with unique data on self-reported reasons for switching in our estimation. Results show that the two new drugs Levitra and Cialis have higher mean effectiveness than the existing drug Viagra, but physicians have large uncertainty regarding the effectiveness for Levitra and side effects for Cialis. Detailing is effective in reducing the uncertainty for effectiveness but much less so for side effects. Based on the results, we investigate the roles of effectiveness and side effects in physicians' prescription choices, and the importance of detailing for new entrants in competing with incumbent drugs. This paper was accepted by J. Miguel Villas-Boas, marketing.

[1]  T. Costigan,et al.  Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. , 2002, The Journal of urology.

[2]  I. Goldstein,et al.  Oral sildenafil in the treatment of erectile dysfunction. 1998. , 1998, The Journal of urology.

[3]  Gregory S. Crawford,et al.  Uncertainty and Learning in Pharmaceutical Demand , 2005 .

[4]  K. Train.  Discrete Choice Methods with Simulation , 2003 .

[5]  Andrew T. Ching,et al.  The effects of detailing on prescribing decisions under quality uncertainty , 2009 .

[6]  M. Degroot.  Optimal Statistical Decisions , 1970 .

[7]  Andrew T. Ching,et al.  Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration , 2001 .

[8]  Pradeep Chintagunta,et al.  Information, learning, and drug diffusion: The case of Cox-2 inhibitors , 2008 .

[9]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[10]  K. Leffler,et al.  Persuasion or Information? The Economics of Prescription Drug Advertising , 1981, The Journal of Law and Economics.

[11]  P. Klemperer.  Markets with consumer switching costs , 1986 .

[12]  Michael P. Keane,et al.  A model of health plan choice:: Inferring preferences and perceptions from a combination of revealed preference and attitudinal data , 1998 .

[13]  P. Klemperer,et al.  Multi-Period Competition with Switching Costs , 1992 .

[14]  Andrew T. Ching,et al.  Measuring the Informative and Persuasive Roles of Detailing on Prescribing Decisions , 2010, Manag. Sci..

[15]  Ying Xie,et al.  The Role of Targeted Communication and Contagion in Product Adoption , 2008, Mark. Sci..

[16]  Paul Klemperer,et al.  Welfare Effects of Entry Into Markets with Switching Costs , 1988 .

[17]  M. Keane,et al.  Decision-Making Under Uncertainty: Capturing Dynamic Brand Choice Processes in Turbulent Consumer Goods Markets , 1996 .

[18]  Toker Doganoglu,et al.  Switching costs, experience goods and dynamic price competition , 2010 .

[19]  Peter E. Rossi,et al.  Response Modeling with Nonrandom Marketing-Mix Variables , 2004 .

[20]  P. Klemperer.  Competition when Consumers have Switching Costs: An Overview with Applications to Industrial Organization, Macroeconomics, and International Trade , 1992 .

[21]  Richard E. Caves,et al.  Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals , 1988, The Journal of Law and Economics.

[22]  Steven Berry,et al.  Differentiated Products Demand Systems from a Combination of Micro and Macro Data: The New Car Market , 1998, Journal of Political Economy.

[23]  Sridhar Narayanan,et al.  Heterogeneous Learning and the Targeting of Marketing Communication for New Products , 2009, Mark. Sci..

[24]  Kenneth E. Train,et al.  Discrete Choice Methods with Simulation , 2016 .

[25]  J. M. Villas-Boas,et al.  Endogeneity in Brand Choice Models , 1999 .

[26]  B. Hamilton,et al.  Learning, Private Information, and the Economic Evaluation of Randomized Experiments , 2003, Journal of Political Economy.

[27]  J. M. Villas-Boas.  Consumer Learning, Brand Loyalty, and Competition , 2004 .

[28]  J. M. Villas-Boas,et al.  Dynamic Competition with Experience Goods , 2006 .

[29]  W. Hellstrom,et al.  Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. , 2002, Journal of andrology.

[30]  Daniel A. Ackerberg.  Empirically Distinguishing Informative and Prestige Effects of Advertising , 2001 .

[31]  Tom F. Lue,et al.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.